Φορτώνει......
COVID-19 and Disease-Modifying Anti-rheumatic Drugs
PURPOSE OF REVIEW: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. RECENT FINDINGS: In patients with autoimmune diseases, baseline glucocorticoid use is...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Curr Rheumatol Rep |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer US
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8065312/ https://ncbi.nlm.nih.gov/pubmed/33893890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-021-00998-9 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|